FENGABINE, A NEW GABAMIMETIC AGENT IN THE TREATMENT OF DEPRESSIVE-DISORDERS - AN OVERVIEW OF 6 DOUBLE-BLIND STUDIES VERSUS TRICYCLICS

被引：20

作者：

MAGNI, G ^{[1
]}

GARREAU, M ^{[1
]}

OROFIAMMA, B ^{[1
]}

PALMINTERI, R ^{[1
]}

机构：

[1] LABS ETUD & RECH SYNTHELAB, CLIN RES DEPT, F-75013 PARIS, FRANCE

来源：

关键词：

D O I：

10.1159/000118485

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

引用

页码：126 / 131

页数：6

共 10 条

[1]

BARTHOLINI G, 1985, PSYCHOPHARMACOL BULL, V21, P385

[2]

GUELFI JD, 1981, ANN MED-PSYCHOL, V139, P199

[3]

Guy W, 1976, ECDEU ASSESSMENT MAN, P218, DOI DOI 10.1016/J.BIOPHA.2016.11.034

[4]

Hamilton M., 1967, BR JSOC CLIN PSYCHOL, V6, P278, DOI [DOI 10.1111/J.2044-8260.1967.TB00530.X, 10.1111/j.2044-8260.1967.tb00530.x]

[5] THE RISK-BENEFIT ASSESSMENT OF ANTIDEPRESSANT DRUGS [J].

HENRY, JA ;

MARTIN, AJ .

MEDICAL TOXICOLOGY AND ADVERSE DRUG EXPERIENCE, 1987, 2 (06) :445-462

[6]

LLOYD KG, 1987, J PHARMACOL EXP THER, V241, P245

[7]

LLOYD KG, 1986, GABA MOOD DISORDERS, P33

[8]

MUSCH B, 1986, BIOL PSYCHIATRY 1985, P920

[9]

SCATTON B, 1987, J PHARMACOL EXP THER, V241, P251

[10]

SUSLER F, 1978, BIOCHEM PHARMACOL, V27, P257